Related Experiment Videos

Intensive lipid lowering in patients with rheumatoid arthritis and previous myocardial infarction: an explorative

Anne G Semb1, Ingar Holme, Tore K Kvien

  • 1Department of Rheumatology, Diakonhjemmet Hospital, NO-0319 Oslo, Norway. a-semb@diakonsyk.no

Rheumatology (Oxford, England)
|October 2, 2010
PubMed

Insights

Rheumatoid arthritis (RA) patients with coronary heart disease (CHD) experienced similar cardiovascular event rates and lipid reductions with statin therapy compared to those without RA. These findings highlight effective secondary prevention in RA patients, despite lower baseline cholesterol levels.

Area of Science:

  • Cardiology
  • Rheumatology
  • Pharmacology

Background:

  • Rheumatoid arthritis (RA) significantly increases the risk of coronary heart disease (CHD).
  • Secondary prevention strategies, including statin use, are crucial for RA patients with established CHD.
  • Limited data exists on statin efficacy in RA patients with CHD.

Purpose of the Study:

  • To evaluate the effect of statin treatment on lipid levels in RA patients with CHD.
  • To assess the incidence of cardiovascular disease (CVD) events in RA patients undergoing statin therapy.
  • To compare outcomes in RA patients versus the general population within the IDEAL study.

Main Methods:

  • Exploratory analysis of the IDEAL study, including 87 RA patients with prior myocardial infarction (MI).
  • Patients were randomized to atorvastatin 80 mg or simvastatin 20-40 mg daily.
  • Lipid levels and composite secondary endpoint (any CVD event) were analyzed over 4.8 years.

Main Results:

  • RA patients exhibited lower baseline total and LDL cholesterol levels compared to non-RA patients.
  • Both atorvastatin and simvastatin demonstrated comparable lipid-lowering effects in RA patients.
  • Cardiovascular event rates were similar between RA patients (26.4%) and the general IDEAL population (28.7%).

Conclusions:

  • Statin therapy provides comparable lipid-lowering efficacy in RA patients with previous MI as in the general population.
  • RA patients with previous MI experienced similar rates of cardiovascular events compared to their non-RA counterparts.
  • Lower baseline cholesterol in RA patients did not alter the effectiveness of statin treatment or CVD event rates.
Abstract

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Rheumatic Heart Disease IV: Nursing Management01:20

Rheumatic Heart Disease IV: Nursing Management

AssessmentA comprehensive assessment is essential in managing a patient with rheumatic heart disease (RHD). Begin with obtaining a detailed medical history, including recent streptococcal infections, a history of rheumatic fever, or previously diagnosed rheumatic heart disease. Assess the patient for symptoms such as fever, chest pain, widespread joint pain (arthralgia), tachycardia, pericardial friction rub, muffled heart sounds, heart murmurs, peripheral edema, subcutaneous nodules, and...
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies01:22

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
Rheumatic Heart Disease I: Introduction01:23

Rheumatic Heart Disease I: Introduction

Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...